Hydrocortisone Acetate Amdipharm Uk Limited

Hydrocortisone Acetate Amdipharm Uk Limited is a prescription injectable solution containing the corticosteroid hydrocortisone acetate. The product is supplied in an unspecified strength for intra‑articular and peri‑articular administration. It belongs to the glucocorticoid class and is marketed in the European Union. It is administered by a clinician in a clinical setting and requires proper aseptic technique. The medication is intended to control inflammation and pain associated with joint disorders.

Hydrocortisone Acetate injectable solution is employed by physicians to manage a range of inflammatory joint conditions, providing localized glucocorticoid activity that reduces swelling, pain, and functional limitation.

- Intra‑articular injection for osteoarthritis pain relief. - Peri‑articular administration in rheumatoid arthritis flare management. - Adjunct therapy for postoperative joint inflammation. - Treatment of synovitis in various arthritic conditions. - Local anti‑inflammatory control in temporomandibular joint disorders. - Management of inflammatory effusion in knee arthroplasty patients. - Injection for acute bursitis of the shoulder. - Use in sacroiliac joint inflammation associated with spondyloarthritis. - Local therapy for inflammatory tenosynovitis of the wrist.

Adverse reactions to intra‑articular or peri‑articular hydrocortisone acetate may vary in frequency and severity.

Common: - Transient pain or swelling at the injection site, typically resolving within a few days. - Localized bruising or discoloration of the skin around the injection area. - Temporary increase in blood glucose levels in patients with diabetes, requiring monitoring. - Mild skin thinning or atrophy at the site of injection, observed with repeated use.

Serious: - Joint infection (septic arthritis) presenting with severe pain, fever, and swelling, requiring urgent medical treatment. - Tendon rupture or weakening, which may lead to loss of function and need for surgical repair. - Significant systemic glucocorticoid effects such as adrenal suppression, manifesting as fatigue, hypotension, or electrolyte imbalance. - Osteonecrosis of the bone, especially with repeated high‑dose injections, leading to joint collapse.

When using hydrocortisone acetate for intra‑articular or peri‑articular injection, clinicians should observe several precautionary measures to minimize risk.

- Assess for active infection at the injection site or systemic infection before administration. - Evaluate patient’s history of diabetes, hypertension, or osteoporosis, as glucocorticoids may exacerbate these conditions. - Use the lowest effective dose and limit the frequency of injections to reduce local tissue damage. - Monitor blood glucose levels in diabetic patients following injection. - Avoid use in patients with known hypersensitivity to corticosteroids or formulation excipients.

Hydrocortisone acetate may interact with other medications; certain combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent systemic corticosteroids, which can increase the risk of systemic glucocorticoid adverse effects. - Live vaccines, because immunosuppression may reduce vaccine efficacy and increase infection risk.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may increase the risk of gastrointestinal irritation when used together. - Anticoagulants or antiplatelet agents, as local injection may exacerbate bleeding tendencies. - Diabetic medications, since glucocorticoid exposure can cause transient hyperglycemia requiring dose adjustment. - Antifungal agents such as ketoconazole, which can inhibit steroid metabolism and increase systemic exposure.